Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial.

Journal: Diabetes care
Published Date: Dec 26, 2017

Abstract

OBJECTIVE: Identifying patients who may experience decreased or increased mortality risk from intensive glycemic therapy for type 2 diabetes remains an important clinical challenge. We sought to identify characteristics of patients at high cardiovascular risk with decreased or increased mortality risk from glycemic therapy for type 2 diabetes using new methods to identify complex combinations of treatment effect modifiers.

Authors

  • Sanjay Basu
    Center for Primary Care and Outcomes Research, Center for Population Health Sciences, Departments of Medicine and Health Research and Policy, Stanford University, Palo Alto, CA basus@stanford.edu.
  • Sridharan Raghavan
    Department of Veterans Affairs Eastern Colorado Healthcare System, Denver, CO.
  • Deborah J Wexler
    Harvard Medical School, Boston, MA.
  • Seth A Berkowitz
    Harvard Medical School, Boston, MA.

Keywords

External Resources

Popular Topics
Recent Journals